

Sophie Postel-Vinay

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/268867/publications.pdf>

Version: 2024-02-01

60
papers

5,700
citations

172457

29
h-index

133252

59
g-index

64
all docs

64
docs citations

64
times ranked

9820
citing authors

#	ARTICLE	IF	CITATIONS
1	Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1. <i>Clinical Cancer Research</i> , 2017, 23, 1920-1928.	7.0	960
2	High-Throughput Genomics and Clinical Outcome in Hard-to-Treat Advanced Cancers: Results of the MOSCATO 01 Trial. <i>Cancer Discovery</i> , 2017, 7, 586-595.	9.4	554
3	Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial. <i>Lancet Oncology</i> , The, 2017, 18, 1590-1599.	10.7	535
4	Targeting FGFR Signaling in Cancer. <i>Clinical Cancer Research</i> , 2015, 21, 2684-2694.	7.0	399
5	Safety, pharmacokinetics, and preliminary activity of the anti-IGF-1R antibody figitumumab (CP-751,871) in patients with sarcoma and Ewing's sarcoma: a phase 1 expansion cohort study. <i>Lancet Oncology</i> , The, 2010, 11, 129-135.	10.7	334
6	Combining epigenetic drugs with other therapies for solid tumours " past lessons and future promise. <i>Nature Reviews Clinical Oncology</i> , 2020, 17, 91-107.	27.6	283
7	Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA): an open-label, multicentre, phase 1/2, basket study. <i>Lancet Oncology</i> , The, 2020, 21, 1155-1164.	10.7	274
8	PARP inhibition enhances tumor cell "intrinsic immunity in ERCC1-deficient non "small cell lung cancer. <i>Journal of Clinical Investigation</i> , 2019, 129, 1211-1228.	8.2	222
9	Mutational Landscape and Sensitivity to Immune Checkpoint Blockers. <i>Clinical Cancer Research</i> , 2016, 22, 4309-4321.	7.0	182
10	Common variants near TARDBP and EGR2 are associated with susceptibility to Ewing sarcoma. <i>Nature Genetics</i> , 2012, 44, 323-327.	21.4	160
11	Targeting the DNA damage response in immuno-oncology: developments and opportunities. <i>Nature Reviews Cancer</i> , 2021, 21, 701-717.	28.4	150
12	Phase I Trials of Molecularly Targeted Agents: Should We Pay More Attention to Late Toxicities?. <i>Journal of Clinical Oncology</i> , 2011, 29, 1728-1735.	1.6	120
13	Towards new methods for the determination of dose limiting toxicities and the assessment of the recommended dose for further studies of molecularly targeted agents " Dose-Limiting Toxicity and Toxicity Assessment Recommendation Group for Early Trials of Targeted therapies, an European Organisation for Research and Treatment of Cancer-led study. <i>European Journal of Cancer</i> , 2014, 50, 2040-2049.	2.8	104
14	Circulating Cell-Free Tumor DNA Analysis of 50 Genes by Next-Generation Sequencing in the Prospective MOSCATO Trial. <i>Clinical Cancer Research</i> , 2016, 22, 2960-2968.	7.0	103
15	The potential of exploiting DNA-repair defects for optimizing lung cancer treatment. <i>Nature Reviews Clinical Oncology</i> , 2012, 9, 144-155.	27.6	96
16	Long-Term Survival in Patients Responding to Anti "PD-1/PD-L1 Therapy and Disease Outcome upon Treatment Discontinuation. <i>Clinical Cancer Research</i> , 2019, 25, 946-956.	7.0	96
17	Challenges of phase 1 clinical trials evaluating immune checkpoint-targeted antibodies. <i>Annals of Oncology</i> , 2016, 27, 214-224.	1.2	86
18	First-in-human phase I study of the bromodomain and extraterminal motif inhibitor BAY 1238097: emerging pharmacokinetic/pharmacodynamic relationship and early termination due to unexpected toxicity. <i>European Journal of Cancer</i> , 2019, 109, 103-110.	2.8	76

#	ARTICLE	IF	CITATIONS
19	Epigenetic modifiers as new immunomodulatory therapies in solid tumours. <i>Annals of Oncology</i> , 2018, 29, 812-824.	1.2	73
20	Can molecular biomarker-based patient selection in Phase I trials accelerate anticancer drug development?. <i>Drug Discovery Today</i> , 2010, 15, 88-97.	6.4	69
21	PBRM1 Deficiency Confers Synthetic Lethality to DNA Repair Inhibitors in Cancer. <i>Cancer Research</i> , 2021, 81, 2888-2902.	0.9	66
22	Defining dose-limiting toxicity for phase 1 trials of molecularly targeted agents: Results of a DLT-TARGETT international survey. <i>European Journal of Cancer</i> , 2014, 50, 2050-2056.	2.8	63
23	First-in-human Phase 1 open label study of the BET inhibitor ODM-207 in patients with selected solid tumours. <i>British Journal of Cancer</i> , 2020, 123, 1730-1736.	6.4	63
24	TPF induction chemotherapy increases PD-L1 expression in tumour cells and immune cells in head and neck squamous cell carcinoma. <i>ESMO Open</i> , 2018, 3, e000257.	4.5	62
25	Ceralasertib (AZD6738), an Oral ATR Kinase Inhibitor, in Combination with Carboplatin in Patients with Advanced Solid Tumors: A Phase I Study. <i>Clinical Cancer Research</i> , 2021, 27, 5213-5224.	7.0	53
26	Phase I Study of GDC-0425, a Checkpoint Kinase 1 Inhibitor, in Combination with Gemcitabine in Patients with Refractory Solid Tumors. <i>Clinical Cancer Research</i> , 2017, 23, 2423-2432.	7.0	50
27	ERCC1 function in nuclear excision and interstrand crosslink repair pathways is mediated exclusively by the ERCC1-202 isoform. <i>Cell Cycle</i> , 2013, 12, 3298-3306.	2.6	37
28	Phase 1 Study of Tazemetostat (EPZ-6438), an Inhibitor of Enhancer of Zeste-Homolog 2 (EZH2): Preliminary Safety and Activity in Relapsed or Refractory Non-Hodgkin Lymphoma (NHL) Patients. <i>Blood</i> , 2015, 126, 473-473.	1.4	37
29	AXL and acquired resistance to EGFR inhibitors. <i>Nature Genetics</i> , 2012, 44, 835-836.	21.4	31
30	Exploiting epigenetic vulnerabilities in solid tumors: Novel therapeutic opportunities in the treatment of SWI/SNF-defective cancers. <i>Seminars in Cancer Biology</i> , 2020, 61, 180-198.	9.6	28
31	Reovirus: Rationale and clinical trial update. <i>Current Opinion in Molecular Therapeutics</i> , 2009, 11, 532-9.	2.8	25
32	JAK Mutations as Escape Mechanisms to Anti-PD-1 Therapy. <i>Cancer Discovery</i> , 2017, 7, 128-130.	9.4	24
33	Immunotherapy for SMARCB1-Deficient Sarcomas: Current Evidence and Future Developments. <i>Biomedicines</i> , 2022, 10, 650.	3.2	24
34	Evidence of pseudoprogression in patients treated with PD1/PDL1 antibodies across tumor types. <i>Cancer Medicine</i> , 2020, 9, 2643-2652.	2.8	21
35	Patient-reported tolerability of adverse events in phase 1 trials. <i>ESMO Open</i> , 2017, 2, e000148.	4.5	20
36	In the immuno-oncology era, is anti-PD-1 or anti-PD-L1 immunotherapy modifying the sensitivity to conventional cancer therapies?. <i>European Journal of Cancer</i> , 2017, 87, 65-74.	2.8	19

#	ARTICLE	IF	CITATIONS
37	DNA repair deficiency sensitizes lung cancer cells to NAD+ biosynthesis blockade. <i>Journal of Clinical Investigation</i> , 2018, 128, 1671-1687.	8.2	19
38	Chromatin Regulators as a Guide for Cancer Treatment Choice. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 1768-1777.	4.1	18
39	Beyond DNA repair: the novel immunological potential of PARP inhibitors. <i>Molecular and Cellular Oncology</i> , 2019, 6, 1-4.	0.7	18
40	Chemotherapy beyond immune checkpoint inhibitors in patients with metastatic colorectal cancer. <i>European Journal of Cancer</i> , 2020, 137, 117-126.	2.8	16
41	Clinical benefit of early phase clinical trial participation for advanced sarcoma patients. <i>Cancer Chemotherapy and Pharmacology</i> , 2011, 68, 423-429.	2.3	14
42	Patterns of progression in patients treated for immuno-oncology antibodies combination. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 221-232.	4.2	12
43	Efficacy of histology-agnostic and molecularly-driven HER2 inhibitors for refractory cancers. <i>Oncotarget</i> , 2018, 9, 9741-9750.	1.8	12
44	A Case-Control Study Brings to Light the Causes of Screen Failures in Phase 1 Cancer Clinical Trials. <i>PLoS ONE</i> , 2016, 11, e0154895.	2.5	10
45	Seeking the driver in tumours with apparent normal molecular profile on comparative genomic hybridization and targeted gene panel sequencing: what is the added value of whole exome sequencing?. <i>Annals of Oncology</i> , 2016, 27, 344-352.	1.2	9
46	Understanding genetic determinants of resistance to immune checkpoint blockers. <i>Seminars in Cancer Biology</i> , 2020, 65, 123-139.	9.6	9
47	Acquired EGFR Mutation as the Potential Resistance Driver to Crizotinib in a MET-Mutated Tumor. <i>Journal of Thoracic Oncology</i> , 2016, 11, e21-e23.	1.1	8
48	Time to progression ratio in cancer patients enrolled in early phase clinical trials: time for new guidelines?. <i>British Journal of Cancer</i> , 2018, 119, 937-939.	6.4	7
49	Impact of COVID-19 Pandemic on Cancer Research. <i>Cancer Cell</i> , 2020, 38, 591-593.	16.8	7
50	How Much Can We Bet on Activity of BET Inhibitors Beyond NUT-1 Midline Carcinoma?. <i>JNCI Cancer Spectrum</i> , 2020, 4, plz092.	2.9	7
51	Coronavirus disease (COVID-19) outbreak and phase 1 trials: should we consider a specific patient management?. <i>European Journal of Cancer</i> , 2020, 137, 235-239.	2.8	7
52	3D Functional Genomics Screens Identify CREBBP as a Targetable Driver in Aggressive Triple-Negative Breast Cancer. <i>Cancer Research</i> , 2021, 81, 847-859.	0.9	7
53	Patients aged over 75 years enrolled in Phase I clinical trials: the <sc>G</sc>ustave <sc>R</sc>oussy experience. <i>International Journal of Cancer</i> , 2016, 138, 875-880.	5.1	5
54	Outcomes and prognostic factors for relapsed or refractory lymphoma patients in phase I clinical trials. <i>Investigational New Drugs</i> , 2018, 36, 62-74.	2.6	3

#	ARTICLE	IF	CITATIONS
55	A Novel Synthetic Lethal Approach to Target <i>MYC</i> -Driven Cancers. <i>Cancer Research</i> , 2022, 82, 969-971.	0.9	3
56	Sustained cancer clinical trial activity in a French hospital during the first wave of the COVID-19 pandemic. <i>Cancer Cell</i> , 2021, 39, 1039-1041.	16.8	2
57	Prognostic factors and outcome of patients with hematological malignancies in phase I trials. <i>Anti-Cancer Drugs</i> , 2017, 28, 540-545.	1.4	1
58	Cardiac troponin I elevation and overall survival among cancer patients receiving investigational compounds during phase I trials. <i>International Journal of Cardiology</i> , 2016, 214, 364-369.	1.7	0
59	Immune Therapies in Phase 1 Trials. , 2018, , 547-563.		0
60	You BETer be aware “ learnings from a negative Phase 1 study. <i>Oncotarget</i> , 2019, 10, 3145-3146.	1.8	0